Tally Health offers a proprietary diagnostic epigenetic age test called TallyAge alongside individualized interventions, personalized lifestyle recommendations, and research-backed longevity supplements. The company positions itself as a consumer biotechnology provider focused on improving healthspan and extending cellular-level longevity. Tally is led by CEO Melanie Goldey and emphasizes a digital member experience to help users integrate TallyAge feedback into daily life. The company plans to expand research and development of new products, add features, and build technology integrations for its digital experience. Tally intends to allocate resources toward technical, business, and strategic development as it scales. Financially, the company has announced a $10M Seed funding round to support these efforts.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2023